Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.36 |
| ▸ | PDE9A | O76083 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29337999 | 0.88 | MEN1 (0.39) | SMN1; SMN2HTTALDH1A1MEN1KMT2A | |
| SCHEMBL19156384 | 0.81 | TLR9 (0.41) | ALDH1A1MEN1KMT2AKDM4EHPGD | |
| SCHEMBL20987766 | 0.80 | KMT2A (0.39) | ALDH1A1MEN1KMT2AKDM4EHPGD | |
| SCHEMBL13384499 | 0.79 | HCAR2 (0.57) | SMN1; SMN2ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL30281214 | 0.79 | HCAR2 (0.57) | SMN1; SMN2ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL12728028 | 0.79 | MKNK1 (0.45) | SMN1; SMN2ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL1002273 | 0.79 | FABP3 (0.41) | SMN1; SMN2ALDH1A1HPGDPDE9ANPC1 | |
| SCHEMBL12553239 | 0.78 | KDM4E (0.40) | SMN1; SMN2ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL12015754 | 0.78 | MKNK1 (0.44) | ALDH1A1MEN1KMT2AKDM4EHPGD | |
| SCHEMBL29503136 | 0.78 | MKNK1 (0.44) | ALDH1A1MEN1KMT2AKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20220402929-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | TOCOPHERX INC (US) | 2022-12-22 | — | — | US | disclosed |
| US-10941152-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | ARES TRADING S.A. (CH) | 2021-03-09 | — | — | US | disclosed |
| US-20190135823-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | TOCOPHERX, INC. | 2019-05-09 | — | — | US | disclosed |
| US-10208055-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | TOCOPHERX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170253605-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | TOCOPHERX, INC. (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170253605-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | TOCOPHERX, INC. (US) | 2017-09-07 | — | — | US | disclosed |
| US-9358231-B2 | Type II RAF kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9180127-B2 | Type II Raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150157629-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8372971-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120220584-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8084618-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100240657-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| US-7696210-B2 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2010-04-13 | — | — | US | disclosed |
| US-7652051-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| WO-2009003998-A2 | ANTIPROLIFERATIVE COMPOUNDS BASED ON 5-MEMBERED HETEROCYCLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208055-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | FSHR, GNRHR, LHCGR | SMN1; SMN2 4771/4885HTT 2453/4885ALDH1A1 4598/4885 |
| US-20120220584-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | SMN1; SMN2 3696/4885HTT 291/4885ALDH1A1 1642/4885 |
| US-20170253605-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | SMN1; SMN2 4771/4885HTT 2453/4885ALDH1A1 4598/4885 |
| US-20190135823-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | SMN1; SMN2 4833/4885HTT 2371/4885ALDH1A1 4610/4885 |
| US-11826365-B2 | Type II raf kinase inhibitors | BRAF, RAF1, ARAF | SMN1; SMN2 2691/4885HTT 3884/4885ALDH1A1 3226/4885 |
| US-20220402929-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | SMN1; SMN2 4833/4885HTT 2371/4885ALDH1A1 4610/4885 |
| US-20150157629-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | SMN1; SMN2 2691/4885HTT 3884/4885ALDH1A1 3226/4885 |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | SMN1; SMN2 3696/4885HTT 291/4885ALDH1A1 1642/4885 |
| US-20100240657-A1 | CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | SMN1; SMN2 755/4885HTT 1760/4885ALDH1A1 174/4885 |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | SMN1; SMN2 2691/4885HTT 3884/4885ALDH1A1 3226/4885 |
| US-10941152-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | FSHR, GNRHR, LHCGR | SMN1; SMN2 4833/4885HTT 2371/4885ALDH1A1 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.